3,4-methylenedioxymethamphetamine

GPTKB entity

Predicate	Object
gptkbp:instanceOf	Hallucinogen entactogen recreational drug stimulant amphetamine derivative
gptkbp:affects	dopamine system norepinephrine system serotonin system
gptkbp:ATCCode	none
gptkbp:CASNumber	42542-10-9
gptkbp:chemicalFormula	C11H15NO2
gptkbp:color	white (powder)
gptkbp:commonName	gptkb:MDMA
gptkbp:developedBy	gptkb:Merck
gptkbp:discoveredBy	gptkb:Anton_Köllisch
gptkbp:discoveredIn	1912
gptkbp:eliminatedIn	urine
gptkbp:halfLife	7 hours
https://www.w3.org/2000/01/rdf-schema#label	3,4-methylenedioxymethamphetamine
gptkbp:IUPACName	1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine
gptkbp:KEGGID	D12672
gptkbp:legalStatus	gptkb:Schedule_I_(US) gptkb:Class_A_(UK) Schedule 9 (Australia)
gptkbp:mainStreet	gptkb:Molly gptkb:Ecstasy
gptkbp:MeSH_ID	gptkb:D008563
gptkbp:metabolism	safrole
gptkbp:molecularWeight	193.25 g/mol
gptkbp:overdoseSymptoms	gptkb:arrhythmia death seizures hyperthermia rhabdomyolysis
gptkbp:predecessor	gptkb:MDA amphetamine
gptkbp:PubChem_CID	gptkb:ChEMBL43002 1555 1615
gptkbp:riskFactor	gptkb:serotonin_syndrome addiction overdose neurotoxicity
gptkbp:routeOfAdministration	injection oral insufflation rectal
gptkbp:sideEffect	anxiety enhanced sensory perception euphoria hyperthermia hyponatremia increased sociability jaw clenching depression (after use)
gptkbp:UNII	K7LJ1Y1Z6V
gptkbp:usedFor	recreational drug psychotherapy (historically)
gptkbp:bfsParent	gptkb:ecstasy gptkb:Ecstasy gptkb:MDMA
gptkbp:bfsLayer	6